 Deciphera Pharmaceuticals NASDAQ:DCPH was upgraded by equities researchers at ValuEngine from a hold rating to a buy rating in a research report issued to clients and investors on Monday, ValuEngine reports. Several other equities research analysts have also commented on DCPH. HC Wainwright upped their price target on Deciphera Pharmaceuticals from 60.00 to 80.00 and ... 